Cytochrome P450s (CYP) comprise a superfamily of enzymes that catalyze the oxidation of a wide variety of xenobiotic chemicals, including drugs and carcinogens. 1-3) Multiple drug therapy is a common therapeutic practice, particularly in patients with several diseases or conditions, and many drug-drug interactions involving metabolic inhibition are being reported.
Research Organization (HAB, Chiba, Japan). 14, 15) Nilvadipine was synthesized and supplied by Fujisawa Pharmaceutical Co., Ltd. 7-Ethoxyresorufin, 7-benzyloxyresorufin, resorufin, tolbutamide, chlorpropamide, chlorzoxazone, and nifedipine were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). S-Mephenytoin, 4Ј-hydroxymephenytoin, methylhydroxytolbutamide, 6-hydroxychlorzoxazone, and oxidized nifedipine were obtained from Ultrafine Chemicals (Manchester, U.K.). 2-Benzoxazoline and methyltestosterone were purchased from Wako Pure Chemicals (Osaka, Japan), and 7-hydroxycoumarin was from Sumika Chemical Analysis Service, Ltd. (Osaka). All other reagents were of the highest purity commercially available.
Determination of Human CYP Activities 7-Ethoxyresorufin O-deethylase activity (CYP1A1/2), coumarin 7-hydroxylase activity (CYP2A6), 7-benzyloxyresorufin O-debenzylase activity (CYP2B6), tolbutamide methylhydroxylase activity (CYP2C8/9), S-mephenytoin 4Ј-hydroxylase activity (CYP2C19), bufuralol 1Ј-hydroxylase activity (CYP2D6), chlorzoxazone 6-hydroxylase activity (CYP2E1), and nifedipine oxidase activity (CYP3A4) in the presence or absence of nilvadipine were determined as described previously. [14] [15] [16] The incubation mixture consisted of 0.2-1 mg/ml of human microsomes, 2.5 mM NADP ϩ , 25 mM glucose-6-phosphate, 10 mM magnesium chloride, 2 units of glucose-6-phosphate dehydrogenase, 100 mM potassium phosphate buffer (pH 7.4), 0.1 mM EDTA, and 5 ml of methanol or 0.5-4 mM nilvadipine dissolved in methanol in a final volume of 500 ml. [14] [15] [16] The substrate was added to the assay system at three different concentrations (around the expected Km, 1/2Km, and 2Km). 14) Determination of Free Fraction in Incubation Mixture The incubation mixture consisted of human microsomes (0.2-1.0 mg/ml), 20 mM nilvadipine, 100 mM potassium phosphate buffer (pH 7.4), and 0.1 mM EDTA in a final volume of 500 ml. 14) After a 5-min incubation at 37°C, the mixture was centrifuged at 105000 g for 60 min at 4°C, 13) and the concentration of nilvadipine in the supernatant was measured by HPLC with an analytical column Inertsil ODS-3 (150ϫ4.6 mm I.D., GL Sciences Inc., Tokyo, Japan). The column temperature was set at 40°C. The elution was conducted with 30% acetnitrile in 20 mM potassium phosphate buffer (pH 7.0) at a flow rate of 1 ml/min, and detection was by UV absorbance at 254 nm.
Data Analysis All data were analyzed using the mean of duplicate determinations, and the inhibition constant (K i ) was estimated by fitting the inhibition curves to Eq. 1 or Eq. 2, when the inhibition type is competitive or noncompetitive, respectively:
where v, S, I, V max , and K m are the velocity of the metabolite formation and the concentrations of substrate and inhibitor, the maximum velocity of the metabolite formation, and the apparent Michaelis-Menten constant, respectively. These equations were fitted to data by means of a computer program (MULTI), 17) and fitting evaluation was carried out using Akaike's information criterion. 18) 
RESULTS AND DISCUSSION
The inhibitory effects of nilvadipine on metabolic activities in human hepatic microsomes are shown in Fig. 1 . Nilvadipine competitively inhibited 7-ethoxyresorufin O-deethylase, coumarin 7-hydroxylase, tolbutamide methylhydroxylase, S-mephenytoin 4Ј-hydroxylase, and nifedipine oxidase activities, and the K i values were 13.0, 35.8, 5.02, 24.5 and 44.3 mM, respectively. On the other hand, no inhibition of CYP2B6-mediated 7-benzyloxyresorufin O-debenzylation, CYP2D6-mediated bufuralol 1Ј-hydroxylation, or CYP2E1mediated chlorzoxazone 6-hydroxylation by nilvadipine at 40 mM concentration was observed (data not shown).
The free fractions of nilvadipine in the incubation mixture (0.2-1 mg protein/ml) were determined at 20 mM concentration around the observed K i values, because the independence or only weak dependence of compound concentration on the microsomal binding of many drugs, including imipramine, propranolol, troglitazone, and amitriptyline, has been shown. [19] [20] [21] [22] The free fractions of nilvadipine estimated by ultracentrifugation were 18.9-27.4% (Table 1) .
When the substrate concentration is much lower than the K m value, the degree of inhibition (R) can be expressed by the following equation, independent of the inhibition type, except in the case of uncompetitive inhibition, 23, 24) Rϭ1/(1ϩI u /K i ) where I u is the unbound concentration of the inhibitor. Additionally, when the absorption rate is maximum, the maximum inflow concentration of the inhibitor into liver (I in,max ) can be expressed as,
where I p,max , R B , k a , D, Q H , and F a represent the maximum plasma concentration of the inhibitor in the circulation, blood-to-plasma concentration ratio, absorption rate constant, dose, hepatic blood flow, and the fraction absorbed from the gastrointestinal tract into the portal vein, respec- tively. After an oral dosing of 4 mg nilvadipine in healthy volunteers, the peak plasma concentration (I p,max ) is 3.48 ng/ml (9.03 nM). 25) Protein binding of nilvadipine in human plasma, which is measured by equilibrium dialysis, is 97.53-98.70% (mean; 98.38%), 26) and R B of nilvadipine in human blood is 0.848. 27) Free fraction of I in,max (I u ) for nilvadipine after an oral dosing of 4 mg is calculated using free fraction in plasma (f u )ϭ0.0162, k a ϭ0.1 min Ϫ1 , Q H ϭ1610 ml/min, F a ϭ1 to avoid false-negative predictions, to be 12.5 nM. Additionally, the K i values were corrected by free fractions of nilvadipine in the incubation mixture (K i,u , Table 2 ). The 1ϩI u /K i,u values for CYP1A1/2, CYP2A6, CYP2C8/9, CYP2C19, and CYP3A4 were close to 1. Based on these estimations, as well as the results that no inhibition of CYP2B6 CYP2D6, or CYP2E1 by nilvadipine was observed, nilvadipine might not affect the pharmacokinetics and metabolism of drugs metabolized by CYPs. There are no clinical reports that nilvadipine increases the blood concentrations of other CYP-metabolized drugs as a result of its inhibition of metabolism.
In conclusion, the present study suggests that nilvadipine would not cause clinically significant interactions with other drugs, which are metabolized by CYPs, via the inhibition of metabolism. 
